<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03343756</url>
  </required_header>
  <id_info>
    <org_study_id>PROLONGSTEM</org_study_id>
    <nct_id>NCT03343756</nct_id>
  </id_info>
  <brief_title>HepaStem Long-Term Safety Registry</brief_title>
  <acronym>PROLONGSTEM</acronym>
  <official_title>HepaStem Long-Term Safety Registry - Registry for Patients Who Have Been Administered HepaStem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Promethera Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Promethera Biosciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients having received at least one infusion of the Investigational Medicinal Product
      (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera
      Biosciences
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2017</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Adverse Events of Specific Interest (AESI)</measure>
    <time_frame>60 months</time_frame>
    <description>Adverse Events of Specific Interest (AESI):
Event with fatal outcome (Death)
Orthotopic Liver Transplantation (OLT) and Outcome.
Development of Malignancy or unwanted tissue formation in different organs (tumor malignant or not).
Disease linked to transmission of adventitious agents or reactivation of latent pathogens.
Any AE which in the opinion of the Investigator has a plausible causal relationship to HepaStem.</description>
  </primary_outcome>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Urea Cycle Disorder</condition>
  <condition>Crigler-Najjar Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who received HepaStem in the interventional studies conducted by Promethera
        Biosciences will be proposed to participate in this PROLONGSTEM study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients having received at least one infusion of HepaStem during a previous
             interventional clinical study conducted by Promethera Biosciences.

        Exclusion Criteria:

          -  Patients who received an OLT and completed 6-month FU documentation prior to the start
             of the PROLONGSTEM study.

          -  Patients who have received mature liver cells or stem cells other than HepaStem prior
             to the start of the PROLONGSTEM study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urea Cycle Disorders, Inborn</mesh_term>
    <mesh_term>Crigler-Najjar Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

